We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Revvity Broadens Relationship With Genomics England To Advance Genomics in the UK

Double helix structure of DNA.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Revvity, Inc. (NYSE: RVTY), announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields.


A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic conditions in England. In the study, which launched earlier this year, Revvity’s Omics laboratory in Manchester, UK will work with Genomics England to advance the early detection of genetic conditions in newborns. Utilizing the chemagic 360™ instrument, Revvity’s team will extract DNA from cord blood samples collected from newborns across England.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“We’re grateful for the opportunity to expand our relationship with Genomics England to make a greater impact in saving the lives of babies with this new project,” said Dr. Madhuri Hegde, Revvity’s senior vice president and chief scientific officer. “Additionally, the choice of Manchester reflects a deliberate commitment to broadening the UK's talent base across the region and to help spread skills in clinical grade molecular genomics.”


Dr. Ellen Thomas, chief medical officer at Genomics England, said, “This partnership is an important contributor to our goal of researching earlier diagnosis and intervention for rare genetic conditions in newborns. By uniting Genomics England’s research expertise with Revvity’s advanced laboratory capabilities, we are proud to reinforce our commitment to advancing genomics research.”

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.